<DOC>
	<DOCNO>NCT00028886</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Thalidomide may stop growth cancer cell stop blood flow cancer . Peripheral blood stem cell transplant use stem cell patient donor may able replace immune cell destroy chemotherapy use kill cancer cell . The donated stem cell may also help destroy remain cancer cell ( graft-versus-tumor effect ) . It yet know whether chemotherapy follow peripheral blood stem cell transplant effective without thalidomide treat multiple myeloma . PURPOSE : This randomized phase III trial study give combination chemotherapy thalidomide see well work compare give combination chemotherapy without thalidomide treat patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Thalidomide Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy doxorubicin , dexamethasone , high-dose melphalan versus without thalidomide , term event-free survival , patient multiple myeloma . - Determine response rate , complete response rate , overall survival , progression-free survival patient treat regimen . - Determine safety toxicity thalidomide combination intensive chemotherapy patient . - Assess value prognostic factor diagnosis individual patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center treatment policy ( 1 course v 2 course high-dose melphalan ) . Patients randomize 1 2 treatment arm . Arm I : - Patients receive induction chemotherapy ( AD ) comprise doxorubicin IV day 1-4 oral dexamethasone day 1-4 , 9-12 , 17-20 . Patients receive oral thalidomide daily begin day 1 continue 2 week start stem cell mobilization . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Patients receive stem cell mobilization chemotherapy comprise cyclophosphamide IV day 1 doxorubicin IV oral dexamethasone day 1-4 ( CAD ) . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 5 continue last apheresis . - Beginning 8-10 week stem cell collection , patient receive low-dose oral thalidomide daily high-dose melphalan IV day -3 -2 intensification . Patients undergo stem cell infusion day 0 . Patients may receive second course high-dose melphalan 2-3 month first course , case , stem cell infusion follow second course melphalan . - Patients receive maintenance therapy oral thalidomide daily disease progression 3 month response . - Beginning 2 month last course , patient HLA-identical sibling donor undergo nonmyeloablative stem cell transplantation radiotherapy . Arm II : - Patients receive induction chemotherapy ( VAD ) comprise vincristine IV doxorubicin IV day 1-4 dexamethasone day 1-4 , 9-12 , 17-20 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Patients receive stem cell mobilization CAD chemotherapy arm I. G-CSF give arm I . - Patients receive high-dose melphalan undergo stem cell infusion arm I . - Patients receive maintenance therapy interferon alfa SC 3 time weekly progression 3 month partial response . - Beginning 2 month last course , patient HLA-identical sibling donor undergo nonmyeloablative stem cell transplantation radiotherapy . All patient follow every 6 month 3 year annually thereafter . PROJECTED ACCRUAL : A total 450 patient ( 225 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Stage II III No systemic amyloid lightchain amyloidosis PATIENT CHARACTERISTICS : Age : 18 65 Performance status : WHO 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No significant hepatic dysfunction* Bilirubin le 1.75 mg/dL* AST/ALT le 2.5 time normal* NOTE : *Unless related myeloma Renal : Not specify Cardiovascular : No severe cardiac dysfunction No New York Heart Association class II , III , IV heart disease Other : HIV negative No active uncontrolled infection No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No known intolerance thalidomide Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Patients 18 55 year age must allocate study randomization allogeneic stem cell transplantation HLAidentical sibling donor Chemotherapy : No 2 prior course melphalan prednisone therapy local myeloma progression No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior local radiotherapy local myeloma progression allow No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>